Antibody Reformatting & Production Service

Introduction What We Can Offer Publication Why Choose Us FAQs Customer Review Related Services Contact Us

As an experienced antibody solution provider, Creative Biolabs has emerged to be an excellent CRO that enables cutting-edge technologies and satisfied services. To support therapeutic antibody discovery, we have developed antibody reformatting and production service to facilitate your early discovery stage.

Accelerate Your Biologics Development!

Antibody reformatting transforms non-human antibodies into human-compatible therapeutics, reducing immunogenicity and optimizing function for clinical translation. Concurrently, efficient antibody production focuses on high-yield, high-quality manufacturing. This combined process is vital for advancing biologics, addressing challenges like protein folding and expression yields, particularly for fragments. Pioneering research demonstrates innovative solutions for efficient production in microbial systems, ensuring native folding and comparable binding affinity, thereby underscoring the feasibility and importance of advanced antibody engineering.

Antibody Reformatting Solutions

Antibody V regions (VH and VL) from a specific antibody can be reformatted into a variety of different fragments including Fab, F(ab)'2, scFv, VHH, minibodies, and also bispecific antibodies combined with a second specificity. Various antibody formats are optimized for tumor or tissue penetration, or expression in production systems. Here are our current available antibody reformatting choices.

Fab

  • Fab is monovalent and is approximately only a third of the size of a whole IgG;
  • Fab has good characterized penetration properties into tissues and faster clearance from circulation;
  • Fab can benefit from the absence of FcR receptor mediated effector functions;
  • Can be easily expressed in non-mammalian expression systems.

F(ab)'2

  • Retain the bivalent binding of an IgG;
  • Without Fc portion which mediates the effector functions via it's interaction with FcR receptors.

scFv

  • Engineered by linking the variable domains of heavy chain and light chain into a single molecule;
  • scFv is only approximately a fifth of the size of a whole IgG;
  • Routinely used for phage display;
  • Linked to a wide range of fusion proteins for specific targeting.

VHH

  • VHH only consists of the variable domain of the heavy chain;
  • It's only approximately a tenth of the size of a whole IgG;
  • Highly stable and amenable to fuse with other proteins;
  • Can be linked to Fc domains to be engineered as a heavy chain only antibodies.

Bispecific

  • Consist of two different binding domains which can target separate antigens;
  • Critically useful when directing an effector cell to a target cell more effectively;
  • Can be made in various formats;
  • Can be designed to customize your requirements as per specific application.

Our capabilities are not limited to above choices. At Creative Biolabs, we can help our clients to design and produce antibody fragments into virtually any formats via our antibody engineering program. We are dedicated to offering the best solutions which are tailored for your specific projects to ensure meeting the desired objectives. Our experienced team will collaborate with our clients from project initiating to results in the minimum amount of time. We aim to be your professional and attentive partner.

Ready to streamline your antibody development? Contact Creative Biolabs to discuss your project timeline and receive a detailed proposal.

Publication

This publication presents a novel antibody fragment format, FabH3, designed to overcome production limitations of traditional Fab fragments. This new format replaces the constant domains of a Fab molecule with engineered IgG1 CH3 domains that can heterodimerize using an "electrostatic steering" approach. The FabH3 molecule can be produced in the cytoplasm of E. coli using the CyDisCo system (catalyzed disulfide-bond formation system). This method yields a natively folded protein with a comparable binding affinity to the target antigen (SARS-CoV-2 RBD) but at higher soluble yields than its traditional Fab counterpart. The study validates that this format design successfully overcomes the folding and production constraints associated with the CH1 domain found in Fabs, regardless of expression conditions. The results suggest that the replacement of constant domains and the CH3 domain-based heterodimerization do not interfere with the folding and function of the variable domains.

Fig.1 Designing an antibody fragment for cytoplasmic expression. (OA Literature)Fig.1 Cytoplasmic expression of modified antibody fragments.1

Why Choose Us?

Creative Biolabs is a leader in the biopharmaceutical industry, offering over ten years of expertise and a commitment to quality.

Key Advantages:

We have more detailed information available; please contact us.

FAQs

Q1: What is the primary benefit of humanizing an antibody?

A1: Humanizing an antibody primarily reduces its immunogenicity in human patients, minimizing the risk of adverse immune responses (HAMA/HAHA) and extending its half-life. This is crucial for ensuring both therapeutic efficacy and patient safety in clinical applications.

Q2: Can Creative Biolabs produce complex antibody formats like bispecific antibodies?

A2: Absolutely! Creative Biolabs specializes in generating various complex antibody formats, including bispecific antibodies, which can target multiple antigens simultaneously for enhanced therapeutic effects. Our advanced engineering platforms are specifically designed to handle such intricate designs with high success rates and robust production.

Q3: What quality control measures are in place for antibody production?

A3: At Creative Biolabs, we employ rigorous, multi-stage quality control throughout the production process. This includes comprehensive purity assessments, aggregation analysis, endotoxin testing, and functional binding assays to ensure your antibodies meet the highest standards for purity, integrity, and biological activity, ready for your critical applications.

Customer Review

  • Overcoming Expression Challenges
    Using Creative Biolabs' antibody reformatting and production services, we successfully expressed a previously intractable antibody fragment in E. coli at yields far exceeding our expectations. Their expertise with the CyDisCo system was a game-changer for our project, saving us months of optimization. - Dr. P***l Sharma
  • Precise Affinity Maintenance
    Creative Biolabs' meticulous approach to humanization ensured that our antibody's binding affinity was perfectly maintained, even with significant sequence changes. The detailed BLI data they provided gave us full confidence in proceeding to in vivo studies. - Prof. K***n Lee

Related Services

To further support your therapeutic development journey, Creative Biolabs offers a suite of complementary services and related options designed to accelerate your research:

Chemokine Production Measurement Service

Creative Biolabs provides an unparalleled platform for chemokine production measurement assays. Their advanced service and powerful technology, backed by highly skilled scientists, are ready to meet your project's specific needs.

Learn More →

Biophysical Characterization

Creative Biolabs assesses biophysical properties to characterize higher-order protein structures and stability. Using techniques like circular dichroism and calorimetry, they analyze protein conformation, function, and stability, as well as kinetic and thermodynamic parameters.

Learn More →

Contact Us

Creative Biolabs is committed to engineering antibodies into various formats, and also offering production services. Once produced, we characterize the antibodies with an extensive suite of functional assays such as ELISA, affinity determination, or other appropriate biological assays. High quality results will be delivered within timeline and budget requirements. To get more information, please contact us for a quote or to schedule a teleconference.

Reference

  1. Tungekar, Aatir A., and Lloyd W. Ruddock. "Design of an alternate antibody fragment format that can be produced in the cytoplasm of Escherichia coli." Scientific Reports 13.1 (2023): 14188. Distributed under Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.1038/s41598-023-41525-3
Loading case studies...
Online Inquiry